SEQENS in the news

SEQENS, advised by Latham & Watkins, is undergoing a financial restructuring to create a more sustainable capital structure, leading to senior lenders becoming shareholders.

Latham & Watkins advised SEQENS on a financial restructuring that will result in senior lenders becoming new shareholders to support the company's long-term development.

A proposed paracetamol price cut in France threatens the profitability of Seqens' new 120-million-euro production facility, which aims to supply half of Europe's needs.

SEQENS's senior lenders will assume majority ownership as part of a financial restructuring, with various law firms advising the involved parties.

Seqens, a pharmaceutical ingredient supplier, is undergoing a lender-led restructuring five years after its LBO due to the chemical industry's structural crisis.

White & Case advised Bpifrance on the financial restructuring of SEQENS Group, leading to senior lenders becoming new shareholders while Bpifrance maintains its partner role.

French President Emmanuel Macron visited Seqens, a pharmaceutical ingredients leader, to support COVID-19 research.

The public can consult the revised Special Intervention Plan for the PCAS-SEQENS chemical site in Bourgoin-Jallieu from September 7 to October 7, 2026, at local administrative offices.

The CellforCure factory in Les Ulis, owned by Seqens, is closing due to a lack of clients and buyers, reflecting a downturn in the cell therapy market and struggles in French bioproduction.

SEQENS reached a preliminary agreement with financial partners to restructure its debt, improve liquidity, and advance its industrial plan, with creditors becoming new shareholders.

Seqens and its lenders agreed to a financial restructuring where senior lenders will gain a majority stake in the pharmaceutical ingredients and specialty chemicals manufacturer.

French CDMO Seqens finalized a financial restructuring agreement with stakeholders, reinforcing its capital structure and enabling strategic plan execution.

Seqens is undergoing a debt restructuring, resulting in its main lenders becoming shareholders, due to financial challenges including client bankruptcies and competitive pressures.

French chemical company Seqens is restructuring its debt, leading its main lenders to become new shareholders due to financial difficulties stemming from client bankruptcies and fierce Asian competition.

Seqens's total employee count is expected to decrease to 1,674 by March 2026, marking a 6.2% decline from its 2023 headcount of 1,785.

Seqens will ignite its Roussillon plant's torch from August 4-9 for scheduled technical maintenance, assuring no danger to the public or environment.

Seqens is launching paracetamol production at its Roussillon site to cover half of European demand by 2027.

Seqens is launching a 120 million euro paracetamol production unit in Roussillon to supply half of Europe's demand.

Seqens is selling its Cell for Cure site in Les Ulis, which manufactures gene and cell therapies, due to a downturn in the European market, potentially impacting 115 jobs.

Seqens is abandoning its bioproduction plant in Les Ulis and exiting the cell and gene therapy market, seeking a buyer for the site.